Table 5

Other dermatological events in patients with rheumatoid arthritis (RA) given TNF-α-blocking therapy

Patient no.
Age (yr)
Sex
Diagnosis
Druga
Active treatment
Event
Clinical description
Localization
Time to event
Biopsy
Comedicationb
Permanent withdrawal anti-TNF-α
Therapy
Course

1
56
f
RA
A
Yes
Lymphomatoid papulosis-like eruption
Macular erythematosquamous lesions
Lower arms, upper legs and trunk
2.6
Yes
naproxen
No
None
Recovery
2
53
f
RA
A
Yes
Rosacea
Diffuse erythema, scaling, telangiectasias
Head and face
1.9
Yes
prednisolone, captopril, indomethacin, midazolam
No
Topical
Persisting
3
74
f
RA
E
Yes
Pruritus
Itch
Trunk
2.5
No
None
No
Topical
Unknown
4
61
f
RA
I
No
Ecchymoses
Ecchymoses
Hands and feet
25.9
No
AZA, prednisolone
No
Topical
Partial recovery
5
58
f
RA
I
Yes
Drug-induced systemic lupus emythematosus
Discoid erythematous lesions, aphthous lesions, ANA positive, anti-ds-DNA positive
Hands, face, scalp
20.0
No
MTX
Yes
Topical and systemic
Recovery, no rechallenge
6
68
m
RA
I
Yes
Transient swelling of unknown cause
Transient swelling 2 × 3 cm
Scalp
20.0
No
MTX, folic acid, naproxen
No
None
Recovery
7
52
f
RA
L
Yes
Dermatomyositis
Livid erythema, raised CPK, decreased proximal muscular strength
Inner upper arms and legs
2.5
Yes
None
Yes
None
Recovery
8
53
m
RA
L
No
Erythema nodosum
Painful erythematous nodules
Lower legs
7.4
Yes
AZA, naproxen, paracetamol
No
Topical
Partial recovery

aA, adalimumab; I, infliximab; E, etanercept; L, lenercept. bMTX, methotrexate; AZA, azathioprine. CPK, creatinine phosphokinase; f, female, m, male.

Flendrie et al. Arthritis Research & Therapy 2005 7:R666   doi:10.1186/ar1724